Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 4(4): e5129, 2009.
Article in English | MEDLINE | ID: mdl-19357765

ABSTRACT

BACKGROUND: To investigate neurobiological correlates of trait anxiety, CD1 mice were selectively bred for extremes in anxiety-related behavior, with high (HAB) and low (LAB) anxiety-related behavior mice additionally differing in behavioral tests reflecting depression-like behavior. METHODOLOGY/ PRINCIPAL FINDINGS: In this study, microarray analysis, in situ hybridization, quantitative real-time PCR and immunohistochemistry revealed decreased expression of the vasopressin gene (Avp) in the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei of adult LAB mice compared to HAB, NAB (normal anxiety-related behavior) and HABxLAB F1 intercross controls, without detecting differences in receptor expression or density. By sequencing the regions 2.5 kbp up- and downstream of the Avp gene locus, we could identify several polymorphic loci, differing between the HAB and LAB lines. In the gene promoter, a deletion of twelve bp Delta(-2180-2191) is particularly likely to contribute to the reduced Avp expression detected in LAB animals under basal conditions. Indeed, allele-specific transcription analysis of F1 animals revealed a hypomorphic LAB-specific Avp allele with a reduced transcription rate by 75% compared to the HAB-specific allele, thus explaining line-specific Avp expression profiles and phenotypic features. Accordingly, intra-PVN Avp mRNA levels were found to correlate with anxiety-related and depression-like behaviors. In addition to this correlative evidence, a significant, though moderate, genotype/phenotype association was demonstrated in 258 male mice of a freely-segregating F2 panel, suggesting a causal contribution of the Avp promoter deletion to anxiety-related behavior. DISCUSSION: Thus, the identification of polymorphisms in the Avp gene promoter explains gene expression differences in association with the observed phenotype, thus further strengthening the concept of the critical involvement of centrally released AVP in trait anxiety.


Subject(s)
Alleles , Anxiety/genetics , Arginine Vasopressin/genetics , Behavior, Animal/physiology , Animals , Anxiety/physiopathology , Arginine Vasopressin/metabolism , Depression/genetics , Depression/physiopathology , Female , Gene Expression Profiling , Humans , Male , Mice , Motor Activity/physiology , Neuropsychological Tests , Oligonucleotide Array Sequence Analysis , Oxytocin/genetics , Oxytocin/metabolism , Paraventricular Hypothalamic Nucleus/metabolism , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Supraoptic Nucleus/metabolism
2.
Eur J Neurosci ; 26(10): 2857-64, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18001282

ABSTRACT

Following secretion from the posterior pituitary, the neuropeptide vasopressin (AVP) stimulates the kidney to retain water, and when released centrally it can contribute to anxiety- and depression-like behaviours. We hypothesized that CD1 mice bred for low trait anxiety (LAB) suffer from a deficit in AVP. Both osmotically stimulated peripheral secretion and intra-paraventricular nucleus (PVN) release of AVP were found decreased in LAB animals compared with normal anxiety (NAB) or high anxiety (HAB) controls. Consequently, in addition to their extreme non-anxiety, LAB mice showed signs of central diabetes insipidus (cDI), including increased fluid intake and reduced urine osmolality, as well as a pathological increase in plasma osmolality upon water deprivation. These cDI symptoms were attenuated by administration of a selective AVP V2 receptor agonist. A single nucleotide polymorphism (SNP) in exon 1 (C(+40)T) of the Avp gene of LAB animals causes an amino acid substitution in the signal peptide of the AVP precursor, and is likely to impair processing and trafficking of the precursor, as suggested by reduced axonal transport of AVP from the hypothalamic PVN, finally contributing to cDI symptoms and low trait anxiety. In an F2 panel, this SNP co-segregated with fluid intake and showed a partial contribution to low anxiety-related behaviour, indicated by its co-segregation with time spent on the open arms of the elevated plus-maze in a subset of F2 mice. Thus, the SNP-associated deficit in plasma and central AVP contributes to signs of cDI and, at least partially, to low trait anxiety, both features being typical of LAB animals.


Subject(s)
Anxiety/genetics , Arginine Vasopressin/deficiency , Diabetes Insipidus/genetics , Polymorphism, Single Nucleotide/genetics , Animals , Anxiety/metabolism , Anxiety/pathology , Behavior, Animal , Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus/drug therapy , Diabetes Insipidus/metabolism , Diabetes Insipidus/pathology , Drinking/genetics , Exons , Exploratory Behavior/physiology , Hemostatics/therapeutic use , Male , Maze Learning/physiology , Mice , Osmolar Concentration , Paraventricular Hypothalamic Nucleus/metabolism , Plasma/physiology , Radioimmunoassay/methods , Urine/physiology , Water Deprivation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...